First of Amgen’s Phase III Sjögren’s disease trials succeeds

Phase 3positivedazodalibepPositive

AI Analysis

Summary

Amgen announced positive Phase III trial results for dazodalibep in Sjögren's disease and is proceeding with a second Phase III study in this underserved market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

First Phase III trial succeeded

Importance:7/10

Sentiment:

0.70

Phase 3Sjögren's diseasepositive trial datadazodalibep

Related Companies

$AMGN

Read the original article

Published by Clinical Trials Arena on September 23, 2026 3:34 PM

Read Original